drugset / Trial / NCT04725110

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

NCT04725110

Phase 2 Withdrawn University of Minnesota
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients on mechanical ventilation.

Timeline

Start
2026-01-15
Primary completion
2030-10-15
Completion
2031-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Liothyronine Small molecule 50 ug Other